University of South Wales

Aravax Appoints Aled Williams as CBO to Spearhead International Expansion of Peanut Allergy Therapy PVX108

4 months ago

• Aravax appointed Aled Williams as Chief Business Officer to bolster its international presence and strategic partnerships. • Williams will focus on expanding the Aravax portfolio and advancing the asset strategy, leveraging his 25 years of biotech and pharma experience. • The appointment supports the Phase 2 development of PVX108, Aravax's lead immunotherapy for peanut allergy, designed for safer and more targeted treatment. • Aravax aims to establish itself as a leader in food allergy treatments through innovative immunotherapies and strategic global outreach.

Low-Dose Triple Combination Pill Shows Superior Blood Pressure Control in Landmark Trial

9 months ago

• A novel low-dose, three-in-one pill (GMRx2) significantly outperformed standard hypertension care in a Nigerian clinical trial. • The GMRx2 group achieved an 81% blood pressure control rate after one month, compared to 55% in the standard care group. • After six months, the GMRx2 group showed a 5.8 mmHg greater reduction in home systolic blood pressure compared to standard care. • George Medicines has submitted GMRx2 to the FDA for hypertension treatment, potentially impacting cardiovascular disease rates globally.